A population-based study in Taiwan showed that LHRH antagonists were associated with a lower risk of composite CV events (ischemic heart disease, stroke, congestive heart failure, or CV death) compared with LHRH agonists across different patient subgroups, which included those with metastatic disease (adjusted HR 0.16; 95% CI 0.04–0.38; P = 0.013), those receiving ADT for > 6 months (adjusted HR 0.30; 95% CI 0.16–0.54; P < 0.0001), and those with pre-existing CVD (adjusted HR 0.16; 95% CI 0.05–0.50; P = 0.0017) (68). This evidence concerns the gene GNRH1 and stroke disorder.